Introduction
Ventricular septal rupture (VSR) is a rare mechanical complication of acute myocardial infarction (MI) in the era of primary percutaneous coronary interventions, but mortality of patients who present with cardiogenic shock (CS) remains still extremely high.
1,2 The optimal therapeutic strategy and timing for surgery in patients with VSR is a matter of ongoing debate. 3 Current ST elevation myocardial infarction (STEMI) guidelines of the European Society of Cardiology (ESC) and the American College of Cardiology Foundation and the American Heart Association (ACCF/AHA) recommend urgent/emergent surgical repair regardless of haemodynamic status at the time of diagnosis. 3, 4 This recommendation is supported by data which showed that mortality associated with a conservative approach reaches 100% and the rupture site can expand abruptly, resulting in sudden haemodynamic collapse in previously stable patients. 2, 5 This recommendation is reasonable for patients who are haemodynamically stable at the time of diagnosis as the preoperative haemodynamic status is a major determinant of survival. 2, 5, 6 However, substantial proportion of patients with VSR is already haemodynamically unstable at the time of diagnosis or following transport to a cardiac surgery centre. These patients have an unacceptably high mortality with an urgent/emergent surgery approach.
1,2 A growing body of published data suggests increasing use of Veno-Arterial Extracorporeal Membrane Oxygenation (V-A ECMO) and other circulatory support devices in patients with VSR complicated by CS. 7 -17 Therefore we analysed our experience with an early ECMO approach in patients with postinfarction VSR complicated by cardiogenic shock.
Methods Ethics
The research was approved by the Ethics Committee of the General University Hospital, Prague (number 1697/16 S-IV). Clinical investigation was conducted according to the principles expressed in the Declaration of Helsinki. Informed written consent was waived due to the retrospective nature of this study and characteristics of study population.
Study design
We used prospective cardiac surgery, catheterization laboratory, coronary care unit and ECMO databases as primary sources to identify eligible patients for the study. Furthermore, we performed a full-text search of computerized patientśhospital records with specific keywords (ventricular septal rupture, ventricular septal defect, defect suture, cardiogenic shock, and mechanical complication). All identified medical records were reviewed for eligibility and all cases meeting the below criteria were included in the present analysis.
Study population
All patients diagnosed with post-infarction VSR at our centre from January 2007 to June 2016 were enrolled into the study. (intraaortic balloon pump counterpulsation (IABP), V-A ECMO), complications and outcomes were analysed in all patients. The diagnosis of VSR was based on transthoracic and/or transoesophageal echocardiography, or angiography, and confirmed by surgery or autopsy. Patients connected to ECMO were cannulated mainly via percutaneous femoro-femoral approach, occasionally by femoro-subclavian or central approach. Patients were anticoagulated by unfractionated heparin (UFH) administered as a bolus of 50-100 units per kg body weight (dose adjusted based on clinical factors) followed by a continuous infusion with target aPTT of 50 to 70 seconds.
Determination of clinical and laboratory data
All characteristics, including clinical history, haemodynamic parameters, angiography, and laboratory results were obtained from institutional database. Data regarding haemodynamic and laboratory characteristics were tracked at admission, 24 hours later, before V-A ECMO initiation, and 24 hours after V-A ECMO initiation, as well as before and following surgery where applicable.
Study objective, safety and outcome assessment
The primary objective of our study was to determine the haemodynamic characteristics before and 24 hours after V-A ECMO implantation in terms of changes of mean arterial pressure, heart rate, arterial lactate levels and pH. Second, we investigated in-hospital complications, 30-day and 1-year mortality for all eligible patients.
Statistical analysis
Continuous variables are reported using mean ± standard deviation (SD). Categorical variables are reported as proportions. Because baseline continuous variables didn't follow normal distribution, the Mann-Whitney U test was performed to compare continuous variables and the Chi-square test was used to compare categorical variables in baseline characteristics and outcomes. Student's t-test was used to compare haemodynamic and laboratory variables with normal distribution recorded before and 24hours after V-A ECMO placement. A p-value of <0.05 was considered significant. All statistical analyses were performed using MedCalc Statistical Software version 16.8.4 (MedCalc Software bvba, Ostend, Belgium; https://www.medcalc.org; 2016).
Results

Baseline characteristics
The study population consisted of 31 patients. Their baseline demographic characteristics according to the presence or absence of CS are listed in Table 1 . Patients in CS at admission to our centre were more frequently male and had higher baseline creatinine values with no other significant differences. 
Haemodynamic characteristics of patients with V-A ECMO
Within the cohort of patients with VSR complicated by CS, 7 out of 14 patients received V-A ECMO support. All patients were indicated to V-A ECMO for refractory CS defined as persistent signs of CS (hypotension <90 mm/Hg, tachycardia >100 per minute and lactate levels >2.0 mmol/l) despite vasopressor and IABP. Five out of 7 patients were cannulated by femoro-femoral approach, 1 patient by subclavian, and 1 by central approach. Table 3 shows haemodynamic characteristics before and 24 hours after V-A ECMO initiation. V-A ECMO improved signs of end-organ perfusion in all patients with lowered lactate levels 24 hours after initiation (7.9 mmol/L vs. Figure 1 shows survival rates within the three groups. Patients without CS had significantly lower 1 year mortality (p<0.05) compared to patients with CS without ECMO support. There were no other significant differences between the groups but patients with VSR and CS who underwent V-A ECMO showed a trend for lower mortality at 30 days and 1 year compared to patients in CS without ECMO therapy (Figure 1 ). Twenty four (77.4%) of 31 patients admitted to our centre underwent VSR surgical repair. All five patients (3 from CS group, 2 from non-shock group) who were considered not eligible for surgery and treated conservatively died within 30 days. for surgical site bleeding. The most common complications in the non-ECMO group (n = 24) were bleeding from the surgical site (n = 6; 25%), IABP site bleeding (n = 3; 12.5%), and upper gastrointestinal bleeding (n = 2; 8.3%). The most frequent infection in ECMO group was sepsis of unknown origin (n = 4; 57%) and pneumonia (n = 3; 42.9%). In patients without ECMO, the most common infections were pneumonia (n = 6; 25%) and urinary tract infections (n = 6; 25%), followed by sepsis of unknown origin (n = 4; 16.7%).
Surgery, 30-Day and 1-Year Outcomes
Discussion
We have demonstrated that the early preoperative use of V-A ECMO in patients with post-infarction VSR complicated by refractory CS provides improved organ perfusion and allows scheduled surgical repair in haemodynamically stabilized condition. Baseline characteristics of our cohort is comparable to previous studies in patients with VSR and/or CS. Patients with signs of CS at admission to our centre were more frequently male and had higher baseline creatinine values, findings also reported among studies in patients with CS. 18, 19 Our results ( Table 2 ) also confirmed published observations that haemodynamic instability in patients with VSR is associated with extremely high mortality. 
Rationale for the use of V-A ECMO in postinfarction VSR complicated by CS
A treatment algorithm with urgent/emergent surgery in postinfarction VSR has been recognized as the only feasible strategy to restore haemodynamic stability and prevent imminent death. 3, 4 This recommendation is reasonable for patients who are haemodynamically stable at the time of diagnosis. 2, 5, 6 However, a substantial part of patients with VSR are already haemodynamically unstable at the time of diagnosis or after transport to a cardiac surgery centre (45% of patients in our study). Moreover, results of previous studies 1, 20 as well as our data suggest that patients with postinfarction VSR who present with CS before surgery have mortality approaching 100% with the standard treatment algorithm recommended by current guidelines. 3, 4 Furthermore, refractory CS before planned surgery usually indicates conservative treatment (44% of patients in the SHOCK trial registry) which means obvious death as shown by previous reports.
1,2 We confirm this observation, all our patients receiving conservative treatment died within 30 days. Our experience suggests that V-A ECMO successfully stabilizes patients with VSR and refractory CS ( Table  2 ) who would not definitely be considered suitable candidates for surgical repair. Similar outcomes have recently been reported by other groups. 7, 8, 10, 11, 13 -17 Therefore, we suggest early V-A ECMO initiation to be considered as a reasonable approach in patients who are haemodynamically unstable before contemplated surgery. To improve outcomes in patients with VSR and CS we strongly advocate for preoperative management tailored to each patient individually (Figure 2) .
Another disadvantage of an emergent/urgent surgery approach is the high probability of repair failure and residual shunt because of the fragility of the necrotic septum. 20 The alternative with the early use of V-A ECMO or other circulatory support devices may prolong time to surgery, allowing consolidation of the freshly infarcted myocardium. 11, 14, 21 On the other hand, the timing of definitive treatment must be customized in each case, as prolonged duration of circulatory support increases the potential for complications including coagulopathy, bleeding and infections, which may further jeopardize planned surgery. 22, 23 Insertion of IABP in patients with VSR is generally recommended. 3, 4 Previous studies showed that early use of IABP with inotropic support may be sufficient to bridge certain patients with VSR to surgical repair. 24, 25 However, IABP seems to provide only partial and short-term haemodynamic benefit and the use of IABP as a sole mechanical supportive measure was associated with continued clinical deterioration. 24 Even our data suggest that for the substantial group of patients with VSR, instituting IABP does not provide sufficient haemodynamic support to proceed with surgery. In such patients V-A ECMO seems to be superior to IABP.
A further challenge in the management of these patients is the definitive treatment of VSR. Debate exists over open repair versus percutaneous closure. 26 We have not used percutaneous closure in our series. In some patients with extensive MI, heart transplantation may remain as an ultimate solution. Successful case reports of patients with VSR and extensive myocardial infarction who were placed on ECMO and underwent heart transplantation have been already published. 8, 27 The use of ECMO can allow for preoperative assessment, as clinical and imaging characteristics are crucial for choosing the optimal therapeutic strategy. V-A ECMO in the VSR treatment algorithm can be used in different ways and perceived as a 'bridge to decision', 'bridge to surgery' followed by a 'bridge to recovery' and eventually 'bridge to LVAD/BiVAD/heart transplantation'. 
V-A ECMO complications
The rate of complications in our critically ill population was high ( 28 and prompt therapy of any bleeding complication.
The second risk is the increased possibility of VSR expansion. The use of peripheral V-A ECMO increases afterload and wall stress, with the risk of left ventricle (LV) distention and inadequate LV unloading. 29 This ECMO related phenomenon may actually be mitigated by the left to right shunt flow through the VSR 13 but the amplified risk of VSR expansion cannot be ruled out as no study to date has addressed this issue. Of note, shunting to the right ventricle may aggravate its dysfunction, a known predictive parameter of mortality in VSR. 30 Moreover, published literature on this topic is limited to a small number of case reports and case series.
7 -11,13,16,17 Furthermore, different timing and choice of therapy in each case does not allow any meaningful analysis.
Despite all above-mentioned complications, it is necessary to underline that postinfarction VSR with CS carries a grave prognosis and the use of ECMO can be life-saving. The complexity of the clinical situation is also reflected in Figure 2 , where haemodynamic status is of crucial importance but also clinical, laboratory and imaging characteristics must be considered and the final decision must be made by the heart team.
Study limitations
Our study has several limitations. The retrospective and single-centre nature of the study restricts the control of confounding factors. Due to the rare occurrence of post-infarction VSR, the number of patients with V-A ECMO support in the present study is small.
Conclusion
Our results suggest that the early use of V-A ECMO in patients with post-infarction VSR provides haemodynamic stabilization and carries a potential to reverse otherwise lethal course of refractory CS. Early V-A ECMO support for postinfarction VSR complicated by CS instead of emergent surgery may present a paradigm shift in the management of these patients. However, efficacy and safety of this treatment method should be confirmed by a larger prospective patient cohort. The risks of V-A ECMO must be carefully considered in each individual case. Bleeding complications are an important limitation of this approach.
